A Safety Review of Pegylated Liposomal Doxorubicin in the Treatment of Various Malignancies

ONCOLOGY

Volumn 11, Issue 10 SUPPL. 12, 1997, Pages 54-62

  Alberts, David S ^a   Garcia, Dava J ^b  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN SULFATE; DOXORUBICIN; VINCRISTINE SULFATE;

ALOPECIA; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG SAFETY; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KAPOSI SARCOMA; LEUKOPENIA; MUCOSA INFLAMMATION; NAUSEA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; SKIN TOXICITY; SOLID TUMOR; STOMATITIS; VOMITING;

EID: 0030731091     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Gabizon A, Papahadjopoulos D: Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors Proc Natl Acad Sci USA 85:6949-6953, 1988.
2. Papahadjopoulos D, Allen TM, Gabigon A, et al: Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 88:11460-11464, 1991.
3. Gabizon A, Isacson R, Libson E, et al: Clinical studies of liposome-encapsulated doxorubicin. Acta Oncologica 33:779-786, 1994.
4. Data on file, Sequus Pharmaceuticals, Menlo Park, CA.
5. Dezube BJ: Safety assessment: DOXIL (doxorubicin HC1 liposome injection) in refractory AIDS-related Kaposi's sarcoma. DOXIL Clinical Series 1:1-8, 1996.
6. Northfelt DW, Martin FJ, Working P, et al: Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: Pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharm 36:55-63, 1996.
7. Northfelt DW, Dezube BJ, Thommes JA, et al: Randomized comparative trial of Doxil vs. Adrinamycin, bleomycin, and vincristine (ABV) in the treatment of severe AIDS-related Kaposi's sarcoma (AIDS-KS). 3rd Conference on Retroviruses and Opportunistic Infections. Abstract 379, 1996.
8. Muggia FM, Hainsworth JD, Jeffers S, et al: Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15:987-993, 1997.
9. Uziely B, Jeffers S, Isacson R, et al: Liposomal doxorubicin: Antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 13:1777-1785, 1995.
10. Madhavan S, Northfelt DW: Lack of vesicant injury following extravasation of liposomal doxorubicin. J Natl Cancer Inst 87:1556-1557, 1995.
11. Von Hoff DD, Maxwell WL, Basa P, et al: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710-717, 1979.
12. Dresdale A, Bonow RO, Wesley R, et al: Prospective evaluation of doxorubicin-induced cardiomyopathy resulting from postsurgical adjuvant treatment of patients with soft tissue sarcomas. Cancer 52:51-60, 1983.
13. Billingham ME, Bristow MR, et al: Evaluation of anthracycline cardiotoxicity: Predictive ability and functional correlation of endomyocardial biopsy. Cancer Treat Symp 3:71-76, 1984.
14. Fischl MA, Krown SE, O'Boyle KP, et al: Weekly doxorubicin in the treatment of AIDS related Kaposi's Sarcoma. AIDS Clinical Trials Group. J Acquir Immun Def Syn 6(3):259-264, 1993.
15. Coukell AJ, Spencer CM: Polyethyleneglycol liposomal doxorubicin. Drugs 53:520-538, 1997.
16. Gordon KB, Tajuddin A, Guitart J, et al: Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy. Cancer 75:2169-2173, 1995.
17. Ranson MR, Carmichael J, O'Byrne K, et al: Treatment of advanced breast cancer with Stealth liposomal doxorubicin (CAELYX): Results of a multicenter phase II trial. J Clin Oncol 15:3185-3191, 1997.
18. Olver IN, Aisner J, Hament A, et al: A prospective study of topical dimethylsulfoxide for treating anthracycline extravasation. J Clin Oncol 6:1732-1735, 1988.
19. Bertelli G, Gozza A, Forno GB, et al. Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: A prospective clinical study. J Clin Oncol 13:2851-2855, 1995.
20. Alberts DS, Bleyer WA: Future development of amifostine in cancer treatment. Semin Oncol 23(suppl F):1-10, 1996.
21. Dorr RT, Lagel KE: Anthracycline cardio-protection by amifostine (WR-2721) and its active metabolite (WR-1065) in vitro. Proc Am Soc Clin Oncol 13:1495, 1994.
22. Wu AW, Rubin HR, et al: A health status questionnaire using 30 items from the medical outcomes study. Med Care 29(8): 786-798, 1991.
23. Stewart S, Jablonowski H, Goebel FD, et al: A randomized comparative trial of liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. J Clin Oncol, 1997 (in press).
24. Lefrak EA, Pitha J, et al: A clinicopathologic analysis of adriamycin cardiomyopathy: Prevention by dose limitation. Cancer 32:302-314, 1973.
25. Gill PS, Wenz J, et al: Lack of cardiac toxicity of liposomal encapsulated daunorubicin after long term use in AIDS related Kaposi's sarcoma. 9th NCI-EORTC Symposium on New Drugs in Cancer Therapy; March 12-15, 1996.